Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
neflamapimod
product3 mentionslast seen Oct 29, 2026
Oral small molecule drug candidate targeting neuroinflammation and neurodegeneration in age-related brain disorders.
Relationships 9
- CervoMed Inc.developsneflamapimod99% confidence3 sources
- neflamapimodapplies toamyotrophic lateral sclerosis treatment99% confidence3 sources
- neflamapimodapplies todementia with Lewy bodies treatment99% confidence3 sources
- U.S. Food and Drug Administrationapprovesneflamapimod99% confidence2 sources
- neflamapimoddepends onp38 MAP kinase inhibition99% confidence2 sources
- neflamapimodapplies toischemic stroke recovery99% confidence2 sources
- neflamapimodapplies tononfluent variant primary progressive aphasia treatment95% confidence1 source
- neflamapimodapplies tonon-fluent variant primary progressive aphasia treatment95% confidence1 source
- neflamapimodapplies toprimary progressive aphasia treatment80% confidence1 source
Relationship
U.S. Food and Drug Administrationapprovesneflamapimod
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 13, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Neflamapimod has received Fast Track Designation from U.S. Food and Drug Administration (FDA) for the treatment of DLB, and Orphan Drug Designation for the treatment of nfvPPA
- filingSEC EDGARSep 28, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the U.S. Food and Drug Administration's (FDA) removal of the previous plasma drug exposure limit